Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ATRA

Atara Biotherapeutics Inc

Apr 14 • 02:23PM ET

5.16

+0.27 5.52 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD NVS ALLO BLUE FATE EDIT CLLS ADAP TVRD IMMP

| Held by: VTI VXF IWC DFAC BTEC DFAS

Scroll to Statements

Index	-	P/E	1.77	EPS (ttm)	2.91	Insider Own	41.12%	Shs Outstand	7.32M	Perf Week	9.55%
Market Cap	42.20M	Forward P/E	-	EPS next Y	-0.78	Insider Trans	-2.62%	Shs Float	4.81M	Perf Month	-20.62%
Enterprise Value	86.52M	PEG	-	EPS next Q	-0.33	Inst Own	25.22%	Short Float	6.80%	Perf Quarter	-12.24%
Income	32.69M	P/S	0.35	EPS this Y	-126.68%	Inst Trans	2.24%	Short Ratio	1.06	Perf Half Y	-63.98%
Sales	120.77M	P/B	-	EPS next Y	-13.02%	ROA	49.91%	Short Interest	0.33M	Perf YTD	-71.48%
Book/sh	-5.26	P/C	4.98	EPS next 5Y	-	ROE	-	52W High	19.15 -73.05%	Perf Year	-11.79%
Cash/sh	1.04	P/FCF	-	EPS past 3/5Y	- -	ROIC	929.16%	52W Low	3.92 31.63%	Perf 3Y	-92.33%
Dividend Est.	-	EV/EBITDA	1.80	Sales past 3/5Y	23.85% -	Gross Margin	82.44%	Volatility	10.88% 9.79%	Perf 5Y	-98.51%
Dividend TTM	-	EV/Sales	0.72	EPS Y/Y TTM	122.88%	Oper. Margin	37.98%	ATR (14)	0.55	Perf 10Y	-99.02%
Dividend Ex-Date	-	Quick Ratio	0.82	Sales Y/Y TTM	-6.33%	Profit Margin	27.07%	RSI (14)	50.84	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	0.82	EPS Q/Q	60.84%	SMA20	5.65%	Beta	-0.31	Target Price	9.33
Payout	0.00%	Debt/Eq	-	Sales Q/Q	-95.13%	SMA50	2.72%	Rel Volume	0.21	Prev Close	4.89
Employees	14	LT Debt/Eq	-	Earnings	Mar 16 AMC	SMA200	-51.41%	Avg Volume	309.26K	Price	5.16
IPO	Oct 16, 2014	Option/Short	No / Yes	EPS/Sales Surpr.	-42.13% -51.17%	Trades		Volume	50,100	Change	5.52%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-13-26	Downgrade	Canaccord Genuity	Buy → Hold	$6
Nov-09-23	Downgrade	Mizuho	Buy → Neutral	$31 → $1
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Downgrade	Citigroup	Neutral → Sell	$8 → $3
Jul-13-22	Downgrade	Stifel	Buy → Hold	$16 → $5
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral	$10
May-10-22	Downgrade	Citigroup	Buy → Neutral	$15 → $8
May-13-21	Upgrade	JP Morgan	Neutral → Overweight	$23 → $29
Dec-09-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$28 → $31
Nov-10-20	Reiterated	H.C. Wainwright	Buy	$26 → $28
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy	$25
Apr-23-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral	$43 → $22
Sep-27-19	Downgrade	Goldman	Neutral → Sell	$14 → $9
Sep-16-19	Downgrade	Jefferies	Buy → Hold	$32 → $15
Jun-04-19	Upgrade	Citigroup	Sell → Neutral	$23 → $24
May-30-19	Initiated	ROTH Capital	Buy

Show Previous Ratings

Apr-01-26 09:00AM	Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA (PR Newswire) +9.30%
Mar-26-26 07:30AM	Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights ATRA (Business Wire) -5.04%
Mar-16-26 04:35PM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance) -9.69% -10.90%
04:05PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress (Business Wire)
Mar-12-26 08:05AM	Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel (Business Wire) +10.75%
08:05AM	Loading…
Mar-03-26 08:05AM	Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel (Business Wire) +10.39%
06:52AM	Pierre Fabre seeks to revive US approval chances for spurned cell therapy (BioPharma Dive)
Feb-23-26 08:00AM	Atara Biotherapeutics Provides a Business Update (Business Wire)
Jan-12-26 11:06AM	FDA Rejects Atara Biotherapeutics' Cell Therapy Again, Stock Sinks (Benzinga) -56.99%
08:00AM	Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO (tabelecleucel) (Business Wire)
06:24AM	AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations (BioPharma Dive)
Nov-12-25 09:11AM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
09:00AM	Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress (Business Wire)
Nov-10-25 08:45AM	Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-07-25 06:45AM	Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? (Zacks)
06:10PM	Loading…
Nov-06-25 06:10PM	Pacira (PCRX) Tops Q3 Earnings Estimates (Zacks) +9.95%
Nov-05-25 06:25PM	Adma Biologics (ADMA) Q3 Earnings Match Estimates (Zacks) -12.53%
Nov-03-25 09:00AM	Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) (PR Newswire) -6.73%
Sep-25-25 09:28AM	Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Sep-03-25 06:00PM	Atara Biotherapeutics Announces Changes to Its Board of Directors (Business Wire)
Aug-19-25 05:00AM	In cell therapy, cost is a hot issue. The industry might need a cold solution. (Pharma Voice)
Aug-11-25 05:53PM	Atara Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance) -5.80% +11.82%
04:01PM	Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress (Business Wire)
Jul-24-25 08:57AM	Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) (PR Newswire)
08:00AM	Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Business Wire)
06:55AM	Rocket lays off staff; Abivax capitalizes on immune drug data (BioPharma Dive)
Jul-15-25 08:00AM	Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. (PR Newswire)
06:31AM	Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug (BioPharma Dive)
Jul-14-25 08:00AM	Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel) (Business Wire)
May-16-25 08:50PM	Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors (Business Wire) -10.12%
08:58AM	Loading…
May-15-25 08:58AM	Atara Biotherapeutics: Q1 Earnings Snapshot (Associated Press Finance) +15.13%
08:35AM	Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress (Business Wire)
08:30AM	Atara Biotherapeutics Announces Pricing of $16Million Offering (Business Wire)
May-14-25 08:25AM	Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 09:10AM	CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-05-25 05:06PM	Atara Biotherapeutics Provides Regulatory Updates on EBVALLO (tabelecleucel) (Business Wire) -7.29% +5.79%
Apr-10-25 08:52AM	Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus (Zacks) -10.02%
Mar-13-25 12:00PM	Atara Biotherapeutics (ATRA) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Mar-07-25 05:10PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -10.72%
04:16PM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress (Business Wire)
Feb-14-25 09:55AM	Wall Street Analysts Think Atara Biotherapeutics (ATRA) Could Surge 33.03%: Read This Before Placing a Bet (Zacks)
08:11AM	Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws (PR Newswire)
Feb-07-25 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.95%
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive) +13.88%
Jan-21-25 01:11PM	FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs (Benzinga) -7.91%
07:30AM	Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO (tabelecleucel) and ATA3219 (Business Wire)
Jan-17-25 07:00AM	Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs (BioPharma Dive) -16.09%
Jan-16-25 12:28PM	Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application (GuruFocus.com) -40.50%
08:30AM	Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel) (Business Wire)
Jan-02-25 12:00PM	Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why (Zacks) +6.39%
Dec-04-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now (GlobeNewswire)
Dec-03-24 07:00AM	Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now (GlobeNewswire)
Nov-27-24 04:01PM	Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-24 04:01PM	Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference (Business Wire) +22.19% -10.45%
Nov-12-24 05:15PM	Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:13PM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress (Business Wire)
Nov-05-24 04:01PM	Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024 (Business Wire) -11.61%
Oct-15-24 12:00PM	Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's What You Should Know (Zacks)
Oct-04-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.81%
Sep-30-24 03:16AM	After scoring a first for an off-the-shelf T cell therapy, can Atara maintain momentum? (Pharma Voice)
Sep-13-24 07:02PM	Redmile Group, LLC Expands Stake in Atara Biotherapeutics Inc (GuruFocus.com) +20.30% -11.52%
Sep-06-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.30% -5.28%
Sep-04-24 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire) +32.89% +10.50%
Sep-03-24 04:16PM	Atara Biotherapeutics Announces $36 Million Registered Direct Offering (Business Wire) -10.39%
Aug-12-24 06:10PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
05:07PM	Atara Biotherapeutics: Q2 Earnings Snapshot (Associated Press Finance)
05:00PM	Atara Biotherapeutics Announces Second Quarter 2024 Financial Results, Operational Progress and Leadership Update (Business Wire)
Aug-07-24 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire) -9.79%
Jul-19-24 06:12AM	US FDA grants priority review for Pierre Fabres EBV+ PTLD (Pharmaceutical Technology)
Jul-17-24 04:13PM	FDA priority review advances Ataras tabelecleucel for viral infection (Pharmaceutical Technology) -12.82%
09:00AM	Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (Business Wire)
07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire) +9.95%
Jul-15-24 12:00PM	All You Need to Know About Atara Biotherapeutics (ATRA) Rating Upgrade to Strong Buy (Zacks) +6.59%
Jul-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
Jul-03-24 07:57PM	Atara Biotherapeutics To Participate at the Stifel Virtual Cell Therapy Forum (Business Wire)
Jun-21-24 04:01PM	Atara Biotherapeutics Ebvallo (tabelecleucel) Wins Prix Galien International Award for Best Product for Orphan/Rare Diseases (Business Wire) -7.53%
Jun-17-24 08:00AM	Atara Biotherapeutics Announces 1-for-25 Reverse Stock Split (Business Wire) -16.93%
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire) +7.68%
Jun-07-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -7.08%
Jun-05-24 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-29-24 04:01PM	Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting (Business Wire) -8.42%
May-20-24 11:57AM	Atara Biotherapeutics Files Biologics License Application for Tabelecleucel with FDA; Shares Rise (MT Newswires) +16.39%
09:25AM	Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA (Business Wire)
May-09-24 10:57PM	ATRA Stock Earnings: Atara Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:17PM	Atara Biotherapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress (Business Wire)
May-03-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -6.00%
Apr-05-24 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-28-24 01:53PM	ATRA Stock Earnings: Atara Biotherapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
09:40AM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:40AM	Atara Biotherapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress (Business Wire)
Feb-29-24 09:05AM	Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy (Business Wire)
Feb-28-24 04:30PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference (Business Wire)
Feb-14-24 09:00AM	Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis (Business Wire)

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Panacea Innovation Ltd	10% Owner	Mar 17 '26	Option Exercise	0.00	259,163	26	307,899	Mar 19 04:30 PM
Grant-Huerta Yanina	Chief Accounting Officer	Mar 02 '26	Sale	5.08	2,104	10,691	31,750	Mar 04 04:28 PM
Nguyen AnhCo	President and CEO	Mar 02 '26	Sale	5.09	2,996	15,237	61,978	Mar 04 04:28 PM
Nguyen AnhCo	Director	Mar 02 '26	Proposed Sale	5.42	3,355	18,184		Mar 02 06:25 PM
Grant-Huerta Yanina	Officer	Mar 02 '26	Proposed Sale	5.42	2,355	12,764		Mar 02 06:24 PM
Panacea Innovation Ltd	10% Owner	Jan 12 '26	Sale	6.07	80,554	489,019	1,324,446	Jan 14 09:16 PM
Panacea Innovation Ltd	10% Owner	Jan 12 '26	Proposed Sale	5.88	40,000	235,200		Jan 12 09:26 PM
Panacea Innovation Ltd	10% Owner	Nov 28 '25	Option Exercise	0.00	48,737	5	48,737	Dec 01 05:00 PM
Nguyen AnhCo	President and CEO	Nov 17 '25	Sale	13.19	2,915	38,437	64,974	Nov 19 04:55 PM
Grant-Huerta Yanina	Chief Accounting Officer	Nov 17 '25	Sale	13.19	1,804	23,788	33,454	Nov 19 04:55 PM
Nguyen AnhCo	Director	Nov 17 '25	Proposed Sale	13.76	3,346	46,041		Nov 17 05:52 PM
Grant-Huerta Yanina	Officer	Nov 17 '25	Proposed Sale	13.76	2,069	28,469		Nov 17 05:50 PM
Nguyen AnhCo	President and CEO	Aug 18 '25	Sale	11.62	2,958	34,360	67,889	Aug 20 04:11 PM
Grant-Huerta Yanina	Chief Accounting Officer	Aug 18 '25	Sale	11.61	1,809	21,009	35,258	Aug 20 04:08 PM
Panacea Innovation Ltd	10% Owner	Aug 15 '25	Buy	12.19	55,000	670,422	1,405,000	Aug 19 08:15 PM
Nguyen AnhCo	Director	Aug 18 '25	Proposed Sale	12.29	3,346	41,122		Aug 18 04:52 PM
Grant-Huerta Yanina	Officer	Aug 18 '25	Proposed Sale	12.29	2,048	25,170		Aug 18 04:47 PM
Panacea Innovation Ltd	10% Owner	Jul 17 '25	Buy	9.64	19,335	186,372	1,350,000	Jul 21 09:00 AM
Grant-Huerta Yanina	Chief Accounting Officer	May 16 '25	Sale	6.76	2,218	15,000	37,067	May 20 04:59 PM
Nguyen AnhCo	President and CEO	May 16 '25	Sale	6.76	3,276	22,156	70,847	May 20 04:58 PM
Nguyen AnhCo	Director	May 16 '25	Proposed Sale	7.61	3,471	26,414		May 16 07:32 PM
Grant-Huerta Yanina	Officer	May 16 '25	Proposed Sale	7.61	2,350	17,884		May 16 07:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATRA

Atara Biotherapeutics Inc

Upgrade your Finviz experience